Minute Insight: Bioventus Completes Cartiheal Acquisition Following Agili-C Approval
Executive Summary
Bioventus exercised a “call option” to acquire Cartiheal for about $315m, plus up to $135m in milestones. The US FDA recently approved Cartiheal’s Agili-C implant to treat knee joint surface lesions.
You may also be interested in...
Smith & Nephew To Acquire Cartiheal For Up To $330M
Smith & Nephew said it will acquire sports medicine technology company Cartiheal for up to $330m to boost its knee injury repair portfolio.
AAOS 2021: Digital Tools In Surgical Ecosystem, Software-Enabled Tech, Robots, Wearables, Sensors
At the live AAOS conference, exhibitors, including major orthopedics players, demoed digital innovations, software-enabled technologies, robotics and smart implants that are expected to create efficiencies in the surgical continuum and provide data to improve outcomes.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.